A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Inclusion Criteria:

• Capable of giving signed informed consent

• Refractory chronic cough (including unexplained chronic cough) for at least one year

• Women of child-bearing potential must use a highly effective contraception methodduring the study and for at least 14 days after the last dose

Exclusion Criteria:

• Current smoker/vaper (all forms of smoking and inhaled substances, including,cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smokingwithin the past 6 months, or those with >20 pack-year smoking history

• Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronicbronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis,uncontrolled asthma, or other significant or progressive airway/respiratory disorderthat might affect cough based on clinician assessment

• Respiratory tract infection within 4 weeks before screening

• Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection at screening

• History of malignancy in the last 5 years

• History of alcohol or drug abuse within the last 3 years

• Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis Bvirus surface antigen, or hepatitis C virus.

• Previous participation in a BLU-5937 trial